Compare CTBI & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTBI | INBX |
|---|---|---|
| Founded | 1903 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 1995 | 2024 |
| Metric | CTBI | INBX |
|---|---|---|
| Price | $68.40 | $92.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $63.00 | ★ $150.00 |
| AVG Volume (30 Days) | 76.7K | ★ 266.0K |
| Earning Date | 04-15-2026 | 05-15-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ 17.79 | N/A |
| EPS | ★ 1.50 | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $14.02 | N/A |
| Revenue Next Year | $4.30 | N/A |
| P/E Ratio | $45.56 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $50.25 | $13.97 |
| 52 Week High | $71.28 | $155.29 |
| Indicator | CTBI | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 53.93 | 43.53 |
| Support Level | $64.34 | $71.31 |
| Resistance Level | $68.49 | $94.52 |
| Average True Range (ATR) | 1.61 | 6.37 |
| MACD | -0.06 | 0.11 |
| Stochastic Oscillator | 53.27 | 38.60 |
Community Trust Bancorp Inc is a bank holding company. The Bank owns all the capital stock of one commercial bank and one trust company, serving small and mid-sized communities in eastern, north-eastern, central, and south-central Kentucky, southern West Virginia, and north-eastern Tennessee. Through its subsidiaries, the Bank is engaged in commercial and personal banking and trust and wealth management activities, which include accepting time and demand deposits; making secured and unsecured loans to corporations, individuals, and others; providing cash management services to corporate and individual customers; issuing letters of credit; renting safe deposit boxes; and providing funds transfer services. The company operates in one reportable segment: community banking services.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.